FOCAL POINTS (Courageous Discourse)

FOCAL POINTS (Courageous Discourse)

Share this post

FOCAL POINTS (Courageous Discourse)
FOCAL POINTS (Courageous Discourse)
Role of Montelukast in the Treatment of Acute COVID-19
Copy link
Facebook
Email
Notes
More

Role of Montelukast in the Treatment of Acute COVID-19

Widely Available Generic Perfect Fit for Multidrug Ambulatory Protocols

Peter A. McCullough, MD, MPH's avatar
Peter A. McCullough, MD, MPH
Apr 23, 2023
∙ Paid
207

Share this post

FOCAL POINTS (Courageous Discourse)
FOCAL POINTS (Courageous Discourse)
Role of Montelukast in the Treatment of Acute COVID-19
Copy link
Facebook
Email
Notes
More
24
4
Share
Upgrade to paid to play voiceover

By Peter A. McCullough, MD, MPH

One of the most remarkable men in the early treatment camp for COVID-19 is South African hero, Dr. Shankaran Chetty. Early in the pandemic, I was fortunate to learn from him how to treat acute ambulatory COVID-19 without the use of hydroxychloroquine or ivermectin. Chetty relied on the principles of timing the illness for cytokine storm and then deploying a combination of anti-inflammatories, antihistamines, steroids, and anticoagulants. Among them is montelukast (Singulair), a leukotriene receptor antagonist used as part of an asthma therapy regimen, to prevent exercise induced bronchoconstriction, and treat acute asthma. Although in the first year of the crisis, there was insufficient evidence for montelukast to be listed in the McCullough Protocol. By 2021, I was using it widely in the acute treatment of COVID-19 with good success.

Keep reading with a 7-day free trial

Subscribe to FOCAL POINTS (Courageous Discourse) to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Peter McCullough MD MPH
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More